Type of antibody:
Primary antibodies, Recombinant antibodies
recombinant human IgG1
Alternative names:
Klrk1, KLR, NKG2D

Specifications for CD314 (NKG2D) Antibody, anti-human, REAfinity™


Clone REA1228 recognizes CD314 (NKG2D), a cell surface receptor of the type II transmembrane receptor NKG2 family. It is expressed on natural killer (NK) cells, CD8
α/β T cells, and γ/δ T cells. Though NKG2D itself possesses no intrinsic signaling capability, ligand engagement while associated to the adaptor proteins DAP10 or DAP12 induces cytolytic activation in NK cells as well as costimulation in certain T cell populations. Ligands for NKG2D are stress-inducible MHC Class I–related MICA, MICB, and UL16-binding proteins, expressed predominantly on epithelial cells and numerous carcinomas.
Additional information: Clone REA1228 displays negligible binding to Fc receptors.

Alternative names

Klrk1, KLR, NKG2D

Detailed product information

Technical specifications

Isotyperecombinant human IgG1
Isotype controlREA Control Antibody (S), human IgG1
Hostcell line
Type of antibodyPrimary antibodies, Recombinant antibodies
AntigenCD314 (NKG2D)
Alternative names of antigenKlrk1, KLR, NKG2D
Molecular mass of antigen [kDa]25
Distribution of antigenNK cells, T cells, CD8+ T cells
Entrez Gene ID22914
RRIDAB_2811655, AB_2811661, AB_2811656, AB_2811662, AB_2811657, AB_2811663, AB_2811658, AB_2811664, AB_2811659, AB_2811660

References for CD314 (NKG2D) Antibody, anti-human, REAfinity™


  1. Maasho, K. et al. (2005)
    NKG2D is a costimulatory receptor for human naive CD8
    T cells.
    J. Immunol. 174: 4480-4484
  2. Bauer, S. et al. (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285: 727-729
  3. Groh, V. et al. (2003) Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc. Natl. Acad. Sci. U.S.A. 100(16): 9452-9457
  4. Moretta, L. and Moretta, A. (2004) Unravelling natural killer function: Triggering and inhibitory human NK receptors. EMBO J. 23: 255-259
  5. Warren, H. S. (2005) The Eighth Human Leucocyte Differentiation Antigen (HLDA8) Workshop: Natural killer cell section report. Cell. Immunol. 236: 17-20
  6. Chaput, N. et al. (2013)
    Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR
    NK cell levels correlate with disease outcome.
    Oncoimmunology 2(2): e23080